These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The further evolution of biotech. Nagle T; Berg C; Nassr R; Pang K Nat Rev Drug Discov; 2003 Jan; 2(1):75-9. PubMed ID: 12509762 [TBL] [Abstract][Full Text] [Related]
8. Overcoming the obstacles in the pharma/biotech industry: 2008 update. Graul AI; Revel L; Rosa E; Cruces E Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic monoclonal antibodies: trends in development and approval in the US. Reichert JM Curr Opin Mol Ther; 2002 Apr; 4(2):110-8. PubMed ID: 12044031 [TBL] [Abstract][Full Text] [Related]
10. Biotech unruffled by setbacks. Glaser V Nat Biotechnol; 1997 Jul; 15(7):610-1. PubMed ID: 9219254 [No Abstract] [Full Text] [Related]
11. Beyond the lab in biotech. With so many drugs in trial, new jobs are opening up. Carmichael M Newsweek; 2002 Sep; 140(13):53. PubMed ID: 12375414 [No Abstract] [Full Text] [Related]
12. Monoclonal antibodies in the clinic. Reichert JM Nat Biotechnol; 2001 Sep; 19(9):819-22. PubMed ID: 11533635 [No Abstract] [Full Text] [Related]
13. FDA requires further trials for antiendotoxin monoclonal antibody products. Am J Hosp Pharm; 1992 Aug; 49(8):1848, 1850. PubMed ID: 1442827 [No Abstract] [Full Text] [Related]
14. Biotech jostles with pharma for slice of HIV market. Katsnelson A Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375 [No Abstract] [Full Text] [Related]
16. How FDA approves biotechnology drugs. Manuel SM; Piascik P Am Pharm; 1995 May; NS35(5):14-5. PubMed ID: 7611131 [No Abstract] [Full Text] [Related]